Evidence map›Paper›PMID 38284719›Full record

ReviewCurrent drug research reviews2025

A Review on Osteoarthritis and its Eradication Approaches: An Update.

Prasoon Pandey, Ritika Singh, Shefali Srivastava, Manoj Kumar Mishra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug research reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Prasoon PandeyShambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, 211015, India.ORCID 0009-0004-9147-6932
Ritika SinghShambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, 211015, India.ORCID 0009-0001-8303-9984
Shefali SrivastavaShambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, 211015, India.ORCID 0009-0008-0673-9654
Manoj Kumar MishraShambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, 211015, India.ORCID 0000-0001-6579-2203

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a disease characterized by degeneration of cartilage or wear and tear. OA is a cause of disability and health issues. It is a disease that affects more than 500 million adults annually worldwide, of which India accounts for about 22 to 39% of OA patients. The most common type of osteoarthritis is knee OA. Pathogenesis of OA requires evolution in basic science and clinical research to enhance our understanding of the pathogenesis and as well as different treatment options. It is mainly classified as primary and secondary OA. The treatment for OA can only reduce the symptoms and cannot cure the disease itself, including pharmacological treatment, like non-steroidal anti-inflammatory drugs (NSAIDs), acting on COX1 (cyclooxygenase 1) and COX2 (cyclooxygenase 2) enzymes. Non-pharmacological treatments for OA include exercise like walking, and aerobic exercise, diet, weight loss, hot and cold therapy, as well as electrotherapy, which improves muscle strength and decreases joint pain. Surgical treatment is the last treatment option for OA patients, which includes arthroscopy and joint replacement therapy. Thus, necessary precautions should be taken for joints to be healthy and disease-free.

Indexed as

OsteoarthritisAnti-Inflammatory Agents, Non-SteroidalHumansAnti-Inflammatory Agents, Non-SteroidalCOX2 inhibitorselectrotherapyepidemiologyNSAIDsOsteoarthritisreplacement therapy.treatment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.